Lundbeck and Pharmexa achieve milestone in Alzheimer collaboration  

Pharmexa's Autovac. technology shows promise in early research phase

Pharmexa and Lundbeck have made important progress in a research collaboration, announcing for the first time that the focus of the collaboration is the development of an AutoVac. product against Alzheimer’s disease. In contrast to traditional symptom relief, the approach constitutes actual treatment of the disease. Proof of concept has now been achieved using relevant animal models, and Lundbeck will progress the project into early preclinical development. The news is reported on the Copenhagen Stock Exchange website.


Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. The company focuses its resources on a number of cancer forms and chronic inflammatory diseases. H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2001, the company’s revenue was DKK 7.7 billion (USD 1 billion). The number of employees is approx. 4,800.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×